JPMorgan Chase & Co. Forecasts Strong Price Appreciation for CG Oncology (NASDAQ:CGON) Stock

CG Oncology (NASDAQ:CGON) had its target price hoisted by equities researchers at JPMorgan Chase & Co. from $65.00 to $91.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 23.93% from the company’s current price.

A number of other research firms have also issued reports on CGON. Royal Bank Of Canada lifted their target price on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Morgan Stanley set a $93.00 target price on CG Oncology in a report on Friday, January 9th. Wall Street Zen upgraded CG Oncology from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. HC Wainwright lifted their target price on CG Oncology from $80.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $79.00.

CG Oncology Trading Up 10.7%

NASDAQ:CGON opened at $73.43 on Friday. The firm has a market cap of $6.20 billion, a PE ratio of -35.47 and a beta of 0.70. The stock has a fifty day moving average price of $62.33 and a 200 day moving average price of $50.52. CG Oncology has a 12-month low of $19.91 and a 12-month high of $73.56.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million during the quarter. Equities analysts forecast that CG Oncology will post -1.31 EPS for the current year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 1,964 shares of CG Oncology stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.40% of the stock is owned by company insiders.

Institutional Trading of CG Oncology

A number of institutional investors have recently bought and sold shares of CGON. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology during the 4th quarter worth about $27,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology during the 3rd quarter worth about $40,000. Comerica Bank lifted its holdings in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the last quarter. Picton Mahoney Asset Management purchased a new stake in CG Oncology during the 4th quarter worth about $118,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of CG Oncology by 33.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after purchasing an additional 972 shares in the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.